510(k) Report

FDA applicant

Spectrawave, Inc.

Bedford, MA6 decisions2023–20250 recalls

FDA records 6 decisions for Spectrawave, Inc. (Bedford, MA) from 2023 to 2025: 6 510(k) clearances. Most are in product codes NQQ (System, Imaging, Optical Coherence Tomography…) and QHA (X-Ray Angiographic Imaging Based Coronary…). Since 2016 its 510(k)s took a median of 90 days from receipt to decision, against 146 for FDA’s reviews in the same codes and years. Its devices cite 7 predicates, 4 of them its own earlier devices. No recall is linked to its devices.

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) refreshed weekly, last Nov 3, 2026

FIG. A — Illustration, radiology panel, where it files most

How often FDA has decided Spectrawave, Inc.’s devices, and how often a recall has named them.

FDA decisions per year

4in 2025

2023: 22025: 4
2023high 4 (2025) · low 0 (2024)2026

2026 so far, outlined.

Recalls per year

No recall linked to its devices since 2023.

FIG. 1 — Spectrawave, Inc. by year, 2023–2026Sources: FDA decision databases, recall and enforcement reports · Data through Oct 25, 2026

Planning a device like Spectrawave, Inc.’s? A 510(k) Report ranks candidate predicates for your device by lineage, citations and recall history, with the review-time outlook.

See the 510(k) Report